Bioventix logo

BVXP - Bioventix News Story

4065p 35.0  0.9%

Last Trade - 3:52pm

Small Cap
Market Cap £209.9m
Enterprise Value £204.1m
Revenue £10.2m
Position in Universe 826th / 1818

Bioventix Plc: Interim Results

Mon 30th March, 2020 7:00am
Bioventix plc
(“Bioventix” or the “Company”)

Unaudited Interim Results for the six months ended 31 December 2019

Bioventix plc (BVXP) (“Bioventix” or “the Company”), a UK company
specialising in the development and commercial supply of high-affinity
monoclonal antibodies for applications in clinical diagnostics, announces its
unaudited interim results for the six-month period ended 31 December 2019.

* Revenue up 21% to £5.3 million (2018: £4.4 million)
* Profit before tax up 31% to £4.3 million (2018: £3.2 million)
* Closing cash balances unchanged at £5.5 million
* Interim dividend up 20% to 36p per share (2018: 30p)
Business review

We are pleased to announce a strong performance for the unaudited interim
results for the six-month period ended 31 December 2019 with revenues for the
half-year of £5.3 million (2018: £4.4 million) up 21% on the previous

Total profits before tax for the half-year increased by 31% to £4.3 million
(2018: £3.2 million).  The cash balances remained very similar, finishing
the period unchanged at £5.5 million. 

Vitamin D antibody sales growth continued at the healthy levels seen during
the previous financial year.  Whilst this is very encouraging, we continue to
see evidence of a plateau in the downstream global vitamin D assay market. 
We have previously commented on the impressive performance of two specific
customers in the downstream vitamin D test market - Diazyme (San Diego, US)
and Boditech (South Korea) – and their sales continued to grow. 

Other revenue streams for the core of established antibodies showed modest
growth during the period.  Added to this were increased sales of a number of
newer antibodies to T4 (thyroxine), androstenedione (a steroid closely related
to testosterone) and biotin (used as a replacement for streptavidin). 

Sales relating to troponin antibodies grew significantly during the period. 
Whilst the actual sales were slightly below our expectation, the percentage
growth provides further evidence of the roll-out of these new tests and
encouragement for the future sales performance. 

Our research activities continue in line with the plans described in the 2019
annual report.  Whilst we will report further on these various projects with
our full year results, we are particularly pleased with the development of our
pollution exposure assay.  We have successfully tested a prototype lab-based
ELISA (enzyme-linked immunosorbent assay) and this will progress towards
commercial kit manufacture during the second half of calendar 2020.  Our hope
is that we will have a lab-based kit available for sale to pollution
researchers sometime during calendar 2021.  In addition to the pollution
research market, it is also possible that the test will have a degree of
utility in the health and safety field (i.e. industrial worker
biomonitoring).  We will initially introduce the test directly to interested
parties before seeking appropriate commercial partners for the future. 

With the exception of COVID-19, the overall context of the business and the
landscape in which we operate has not materially changed since the 2019 annual
report and we draw the attention of any new shareholders to this report. 

We have continued with the development of our Farnham laboratory.  The work
on our manufacturing facilities has been completed and we are now fully
operational.  The last remaining phase of the development work (cost ~£100k)
covering the technology development lab is planned for later in 2020. 

In relation to the comments below regarding COVID-19, Bioventix is a resilient
business and the Board will continue to follow our established dividend
policy.  For the period under review, the Board is pleased to announce an
interim dividend of 36p per share which represents a 20% increase on last

The shares will be marked ex-dividend on 9 April 2019 and the dividend will be
paid on 28 April 2019 to shareholders on the register at close of business on
14 April 2019. 

We would like to offer some comments on COVID-19 and the possible impact on
Bioventix, accepting that perspectives on the infection have tended to be
overtaken by rapidly changing events.  Like many companies, we will be
subject to the effects of COVID-19.  Circumstances have changed quickly
during the last few weeks and therefore we will limit our comments to some
general observations that we believe to be accurate.  In most affected
countries, healthcare and associated products and services have been
prioritised and so we expect that our customers will continue to operate and
that we will continue to supply antibodies to them.  Within the field of our
customers in downstream in vitro diagnostics, it is possible that some routine
diagnostic testing could be reduced as hospitals refocus towards
virus-infected patients and this could have an impact on Bioventix into the
future.  Regarding our own activities in Farnham, the welfare of our staff is
our top priority.  We will be following Government guidelines on working
practices which could result in staff shortages.  During 2020, we will aim to
maintain the production and supply of commercial SMAs to our customers.  We
have already implemented a raw material purchasing strategy that minimises the
possibility of reagent supply shortages and we already hold large stocks of
final products which offers a degree of buffering against adverse effects. 

In conclusion, we are encouraged by the performance for the six months ended
December 2019 and pleased with the continued success of our vitamin D antibody
and core antibody business.  We remain optimistic about our troponin revenues
and the success of these high sensitivity troponin products around the
world.  Whilst we are mindful as to the potential impact of COVID-19, we
currently expect further progress in the second half of the year. 

I J Nicholson

Chief Executive Officer                 Non-Executive Chairman

For further information please contact:

 Bioventix plc Peter Harrison                   Chief Executive Officer              Tel: 01252 728 001  
 finnCap Ltd Geoff Nash/Simon Hicks Alice Lane  Corporate Finance Corporate Broking  Tel: 020 7220 0500  

About Bioventix plc:

Bioventix ( specialises in the development and commercial
supply of high-affinity monoclonal antibodies with a primary focus on their
application in clinical diagnostics, such as in automated immunoassays used in
blood testing. The antibodies created at Bioventix are generated in sheep and
are of particular benefit where the target is present at low concentration and
where conventional monoclonal or polyclonal antibodies have failed to produce
a suitable reagent. Bioventix currently offers a portfolio of antibodies to
customers for both commercial use and R&D purposes, for the diagnosis or
monitoring of a broad range of conditions, including heart disease, cancer,
fertility, thyroid function and drug abuse. Bioventix currently supplies
antibody products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its shares are
traded on AIM under the symbol BVXP.

The information communicated in this announcement contains inside information
for the purposes of Article 7 of the Market Abuse Regulation (EU) No.

for the six month period ended 31 December 2019

                                                 Six months ended 31 Dec 2019    Six months ended 31 Dec 2018 
                                                                            £                               £ 
 TURNOVER                                                           5,265,270                       4,364,665 
 Cost of sales                                                      (393,673)                       (438,160) 
 GROSS PROFIT                                                       4,871,597                       3,926,505 
 Administrative expenses                                            (643,819)                       (655,873) 
 Share option charge                                                 (67,294)                        (67,294) 
 Difference on foreign exchange                                        80,258                          24,680 
 Research & development tax credit adjustment                           5,369                           8,319 
 OPERATING PROFIT                                                   4,246,111                       3,236,337 
 Interest receivable                                                   17,521                           9,662 
 Interest payable                                                         (0)                             (0) 
 PROFIT ON ORDINARY ACTIVITIES BEFORE TAXATION                      4,263,632                       3,245,999 
 Tax on profit on ordinary activities                               (700,893)                       (499,183) 
 PROFIT FOR THE FINANCIAL PERIOD                                    3,562,739                       2,746,816 
 Earnings per share for the period:                                                                           
 Basic                                                                 69.28p                          53.44p 
 Diluted                                                               68.14p                          52.54p 

as at 31 December 2019

                                                      31 Dec 2019    31 Dec 2018 
                                                                £              £ 
 FIXED ASSETS                                                                    
 Intangible fixed assets                                        0              0 
 Tangible fixed assets                                    718,921        524,761 
 Investments                                              579,375        388,377 
                                                        1,298,296        913,138 
 CURRENT ASSETS                                                                  
 Stocks                                                   219,007        258,814 
 Debtors                                                3,814,985      3,368,057 
 Cash at bank and in hand                               5,530,539      5,456,257 
                                                        9,564,531      9,083,128 
 CREDITORS : amounts falling due within one year        (971,878)      (797,616) 
 NET CURRENT ASSETS                                     8,592,653      8,285,512 
 TOTAL ASSETS LESS CURRENT LIABILITIES                  9,890,949      9,198,650 
 PROVISIONS FOR LIABILITIES                                                      
 Deferred Tax                                              63,020         31,989 
 NET ASSETS                                             9,827,929      9,166,661 
 CAPITAL AND RESERVES                                                            
 Called up share capital                                  257,134        257,034 
 Share premium account                                    435,908        414,608 
 Capital redemption reserve                                 1,231          1,231 
 Profit and loss account                                9,133,656      8,493,788 
 SHAREHOLDERS' FUNDS                                    9,827,929      9,166,661 

for the six month period ended 31 December 2019

                                                                                                       31 Dec 2019    31 Dec 2018 
                                                                                                                 £              £ 
 CASHFLOW FROM OPERATING ACTIVITIES                                                                                               
 Cash flows from operating activities  Profit for the financial year                                     3,562,739      2,746,816 
 Depreciation of tangible fixed assets                                                                      57,391         30,349 
 Interest received                                                                                        (17,521)        (9,662) 
 Taxation                                                                                                  224,267       (90,014) 
 Decrease / (increase) in stocks                                                                            20,288         24,276 
 Decrease / (increase) in debtors                                                                          118,930        448,733 
 (Decrease) /increase in creditors                                                                          28,574         63,281 
 Share option charge                                                                                        67,294         67,294 
 Other tax movements                                                                                       (5,369)        (8,319) 
 Net cash generated from operating activities                                                            4,056,593      3,272,754 
 Cash flows from investing activities                                                                                             
 Purchase of tangible fixed assets                                                                       (261,492)       (57,307) 
 Interest received                                                                                          17,521          9,662 
 Purchase of unlisted and other investments                                                              (190,998)       (96,953) 
 Net cash from investing activities                                                                      (434,969)      (144,598) 
 Cash flows from financing activities                                                                                             
 Issue of ordinary shares                                                                                        0            100 
 Movement on share premium account                                                                               0         19,500 
 Dividends paid                                                                                        (4,628,407)    (4,678,013) 
 Interest paid                                                                                                 (0)            (0) 
 Net cash used in financing activities                                                                 (4,628,407)    (4,658,413) 
 Cash and cash equivalents at the beginning of the year                                                  6,537,322      6,986,514 
 Cash and cash equivalents at the end of the year                                                        5,530,539      5,456,257 
 Cash and cash equivalents at the end of the year comprise:                                                                       
 Cash at bank and in hand                                                                                5,530,539      5,456,257 


Notes to the financial information

1.   While the interim financial information has been prepared using the
company’s accounting policies and in accordance with Financial Reporting
Standard 102, the announcement does not itself contain sufficient information
to comply with Financial Reporting Standard 102.

2.   This interim financial statement has not been audited or reviewed by
the auditors.

3.   The accounting policies which were used in the preparation of this
interim financial information were as follows:

   3.1  Basis of preparation of financial statements                                                                      
        The financial statements have been prepared under the historical cost convention and in accordance with FRS 102.  


   3.2  Revenue                                                                                                                                                                   
        •Turnover is recognised for product supplied or services rendered to the extent that it is probable that the economic benefits will flow to the Company and the turnover  
        can be reliably measured. Turnover is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other     
        sales taxes. The following criteria determine when turnover will be recognised:  •Direct sales are recognised at the date of dispatch.  •Subcontracted R & D income is    
        recognised based upon the stage of completion at the year end.  •Annual licence revenue is recognised, in full, based upon the date of the invoice, and royalties are     
        accrued over the period to which they relate. Revenue is recognised based on the returns and notifications received from customers and in the event that subsequent       
        adjustments are identified, they are recognised in the period in which they are identified.                                                                               


   3.3  Intangible fixed assets and amortisation                                                                                                                                                                                                   
        Goodwill is the difference between amounts paid on the acquisition of a business and the fair value of the identifiable assets and liabilities. It is amortised to the Profit and loss account over its estimated economic life.           
        Amortisation is provided at the following rates:                                                                                                                                                                                           
                                                                                                      Goodwill                                       ?                                              Over 10 years                                  
                                                                                                      Know how                                       ?                                              Over 10 years                                  


   3.4  Tangible fixed assets and depreciation                                                                                                                                                                                                                                                                                                    
        Tangible fixed assets are stated at cost less depreciation. Depreciation is not charged on freehold land. Depreciation on other tangible fixed assets is provided at rates calculated to write off the cost of those assets, less their estimated residual value, over their expected useful lives on the following bases:                
                                                                                                                      Freehold property                                      ?                                                      2% straight line                                                                                              
                                                                                                                      Plant and equipment                                    ?                                                      25% reducing balance                                                                                          
                                                                                                                      Motor Vehicles                                         ?                                                      25% straight line                                                                                             
                                                                                                                      Equipment                                              ?                                                      25% straight line                                                                                             


   3.5  Valuation of investments                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
        Investments in unlisted Company shares, whose market value can be reliably determined, are remeasured to market value at each balance sheet date. Gains and losses on remeasurement are recognised in the Statement of comprehensive income for the period. Where market value cannot be reliably determined, such investments are stated at historic cost less impairment.                                                                                                                                                   
   3.6  Stocks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
        Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost includes all direct costs and an appropriate proportion of fixed and variable overheads.  At each balance sheet date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.                                                
   3.7  Debtors                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
        Short term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.                                                                                                                                                                                                                                                         
   3.8  Cash and cash equivalents                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
        Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.  In the Statement of cash flows, cash and cash equivalents are shown net of bank overdrafts that are repayable on demand and form an integral part of  
        the Company's cash management.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                


   3.9  Financial instruments                                                                                                                                                                                                                                                                                     
        The Company only enters into basic financial instruments transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in non-puttable ordinary shares.  


   3.10  Creditors                                                                                                                                                                 
         Short term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction   
         costs, and are measured subsequently at amortised cost using the effective interest method.                                                                               
   3.11  Foreign currency translation                                                                                                                                              
         Functional and presentation currency                                                                                                                                      
         The Company's functional and presentational currency is GBP.                                                                                                              
         Transactions and balances                                                                                                                                                 
         Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.  At each period end foreign     
         currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the   
         transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.                                            
   3.12  Finance costs                                                                                                                                                             
         Finance costs are charged to the Statement of comprehensive income over the term of the debt using the effective interest method so that the amount charged is at a       
         constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.                           
   3.13  Dividends                                                                                                                                                                 
         Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved  
         by the shareholders at an annual general meeting. Dividends on shares recognised as liabilities are recognised as expenses and classified within interest payable.        
   3.14  Employee benefits-share-based compensation                                                                                                                                
         The company operates an equity-settled, share-based compensation plan. The fair value of the employee services received in exchange for the grant of the options is       
         recognised as an expense over the vesting period. The total amount to be expensed over the vesting period is determined by reference to the fair value of the options     
         granted. At each balance sheet date, the company will revise its estimates of the number of options are expected to be exercisable. It will recognise the impact of the   
         revision of original estimates, if any, in the profit and loss account, with a corresponding adjustment to equity. The proceeds received net of any directly attributable 
         transaction costs are credited to share capital (nominal value) and share premium when the options are exercised.                                                         
   3.15  Research and development                                                                                                                                                  
         Research and development expenditure is written off in the year in which it is incurred.                                                                                  


   3.16  Pensions                                                                                                                                                                  
         Defined contribution pension plan                                                                                                                                         
         The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a 
         separate entity. Once the contributions have been paid the Company has no further payment obligations.  The contributions are recognised as an expense in the Statement of 
         comprehensive income when they fall due. Amounts not paid are shown in accruals as a liability in the Statement of financial position. The assets of the plan are held    
         separately from the Company in independently administered funds.                                                                                                          
   3.17  Interest income                                                                                                                                                           
         Interest income is recognised in the Statement of comprehensive income using the effective interest method.                                                               
   3.18  Provisions for liabilities                                                                                                                                                
         Provisions are made where an event has taken place that gives the Company a legal or constructive obligation that probably requires settlement by a transfer of economic  
         benefit, and a reliable estimate can be made of the amount of the obligation.  Provisions are charged as an expense to the Statement of comprehensive income in the year  
         that the Company becomes aware of the obligation, and are measured at the best estimate at the Statement of financial position date of the expenditure required to settle 
         the obligation, taking into account relevant risks and uncertainties.  When payments are eventually made, they are charged to the provision carried in the Statement of   
         financial position.                                                                                                                                                       
   3.19  Current and deferred taxation                                                                                                                                             
         The tax expense for the year comprises current and deferred tax. Tax is recognised in the Statement of comprehensive income, except that a charge attributable to an item 
         of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in 
         equity respectively.  The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date 
         in the countries where the Company operates and generates income.                                                                                                         
         Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the Statement of financial position date, except that:  
         · The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or     
         other future taxable profits; and · Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.              
         Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the           
         differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities        
         acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the         
         reporting date.                                                                                                                                                           

Copyright (c) 2020 PR Newswire Association,LLC. All Rights Reserved
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.